홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

빈크리스틴 황산염

Vincristine Sulfate

HCID 249332
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
2068-78-2
표준 SMILES
CC[C@]1(O)C[C@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C=O)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1.O=S(=O)(O)O
InChIKey
AQTQHPDCURKLKT-JKDPCDLQSA-N
분자식
C46H56N4O10.H2O4S
평균 분자량
923 g/mol
단동위원소 질량
922.36702371

개요

Vincristine Sulfate can cause developmental toxicity according to state or federal government labeling requirements.

이름 및 식별자

우선 이름
Vincristine Sulfate
IUPAC
methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate;sulfuric acid
현지명
빈크리스틴 황산염
영어명
Vincristine sulfate
분자식
C46H58N4O14S
분자량
923.04

이름 및 동의어

Vincristine sulfate2068-78-2OnkovinVCR sulfateVincristine sulphateKyocristineVincrisulLilly 37231NovopharmVincristini sulfasLeurocristine sulfateVincaleukoblastine, 22-oxo-, sulfate (1:1) (salt)
이름 더 보기
빈크리스틴황산염빈크리스틴황산염(VINCRISTINESULFATE)oncovinVCRvincristinVincristin SulfateVinorelbine SulfateVINCRISTINE SULFATE USPVINCRISTINE SULFATE SALT
NSC 67574VincrexLeurocristine, sulfate (1:1) (salt)Vincristine, sulfateLeurocristine, sulfateVincasar PFSNSC67574Vincristine Sulfate PFS

데이터베이스 식별자

CAS
2068-78-2
PubChem CID
249332
DTXSID

물성

구조 계산 물성

극성 표면적
254 Ų
수소 결합 공여자 수
5
수소 결합 수용자 수
16
회전 가능 결합 수
10
무거운 원자 수
65
형식 전하
0
복잡도
1,830

실험 및 물리화학적 성질

Solubilitygreater than or equal to 10 mg/mL at 75 °F (NTP, 1992)
Human Drugs · 3건

Breast Feeding; Lactation; Milk, Human; Antineoplastic Agents; Antimitotic Agents

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point531 °F approximately (NTP, 1992)
Physical DescriptionVincristine sulfate appears as an anticancer drug. White to slightly yellow, amorphous or crystalline powder. Sensitive to light. Odorless. pH (0.1% solution) 3.5 - 4.5. (NTP, 1992)
Collision Cross Section281 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

물리화학적 성질

녹는점
300 °C · 300 °C
끓는 점
273 · 273-281 °C
저장 조건
-20 °C · Sealed in dry,Store in freezer, under -20°C
용해도
20 mg/mL · 메탄올: 용해성20mg/mL
물리적 상태
동결건조된 분말
색상
흰색에서 황백색까지
수용성
24 · 24 ºC에서 >=1g/100mL

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Danger

H300 (91.5%): Fatal if swallowed [Danger Acute toxicity, oral]

P203, P264, P270, P280, P301+P316, P318, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 47 reports by companies from 9 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Regulatory InformationHazard Traits - Developmental Toxicity
Other Safety InformationIMAP assessments - Vincaleukoblastine, 22-oxo-, sulfate (1:1) (salt): Human health tier I assessment
DOT LabelPoison
Fire HazardsFlash point data for this chemical are not available; however, it is probably combustible. (NTP, 1992)
Health Hazards · 1건

SYMPTOMS: The following symptoms of exposure have occurred during intravenous use. Symptoms of exposure include bone marrow depression, peripheral neuropathy, colicky abdominal pain, constipation and alopecia. Other symptoms include neuromuscular and neurological disturbances, gastrointestinal upset and leucopenia. It has caused impaired walking, convulsions, hypertension, inappropriate antidiuretic hormone (ADH) secretion, jaw pain, paresthesias in the fingers and toes, sensory impairment, headache, loss of deep tendon reflexes, parotid gland pain, optic atrophy and blindness. It has also caused acute uric acid nephropathy, myocardial infarction, ocular toxicity (ptosis, other ocular muscle paresis, and 5th and 7th nerve involvement); laryngeal nerve paralysis causing hoarseness or cough, depression of the Achilles tendon reflex, muscle pain, weakness, motor weakness, quadriparesis, numbness and tingling of the fingers and toes, malaise, depression, psychoses, neuromyopathy, peripheral neuritis, adynamic ileus, and permanent central nervous system damage. Exposure may cause paresthesia, foot drop, ataxia, athetosis, thrombocytosis and coma. Exposure may also cause granulocytopenia, thrombocytopenia, hypoplasia of all elements of bone marrow, nausea, vomiting, anorexia, neuritic pain and motor difficulties. Other effects may include cranial nerve neuropathy including optic nerve neuropathy and injury to the retina; cataracts, facial paralysis, diplopia and corneal hypesthesia. It may cause anemia, polyuria, dysuria, fever, tingling and numbness of the extremities, abdominal obstruction, ischemic cardiac toxicity and syndrome of hyponatremia. It may also cause diarrhea, sensory loss, slapping gait, muscle wasting, generalized sensorimotor dysfunction, paralytic ileus, abdominal cramps, rash, oral ulceration, intestinal necrosis and/or perforation, urinary retention due to bladder atony cranial nerve manifestations including isolated paresis and/or paralysis of muscles controlled by cranial motor nerves; pharyngeal pain, bone pain, back pain, limb pain, myalgias, renal or adrenal disease, hypotension, dehydration, azotemia and clinical edema. Effects on the autonomic nervous system have been reported. It may cause irritation of the skin, and congenital malformation in the fetus.

화학 및 산업

약리 정보

Metabolism/Metabolites · 1건

Hepatic. Cytochrome P450 isoenzymes of the CYP3A subfamily facilitate the metabolism of vincristine. Route of Elimination: The liver is the major excretory organ in humans and animals. 80% of an injected dose of vincristine sulfate is excreted via feces. 10 - 20% is excreted via urine. Half Life: When intravenously injected into cancer patients, a triphasic serum decay patten was observed. The initial, middle, and terminal half-lives are 5 minutes, 2.3 hours, 85 hours respectively. The range of the terminal half-life is humans is 19 - 155 hours.

FDA Pharmacological Classification · 2건

VINCRISTINE SULFATE

Vinca Alkaloids [CS]; Vinca Alkaloid [EPC]

MeSH Pharmacological Classification · 2건

Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.

Agents that interact with TUBULIN to inhibit or promote polymerization of MICROTUBULES.

용도 및 제조

Uses · 1건

Treatment of acute lymphocytic leukemia (ALL), Hodgkin lymphoma, non-Hodgkin lymphomas, Wilms' tumor, neuroblastoma, rhabdomyosarcoma. Liposomal vincristine is indicated for the treatment of relapsed Philadelphia chromosome-negative (Ph-) acute lymphoblastic leukemia (ALL).

응용 분야

용도Vincristine sulfate, is used as an anticancer agent, microtubule disrupter, Induces apoptosis in human lymphoma cells. Other applications include as a cell cycle arresting, apoptotic inducing alkaloid.

일반 설명Vincristine sulfate appears as an anticancer drug. White to slightly yellow, amorphous or crystalline powder. Sensitive to light. Odorless. pH (0.1% solution) 3.5 - 4.5. (NTP, 1992)

상·하류 제품 정보

관련 반응

7건
반응 기록 만들기
HRID 437029 반응식
HRID 437029반응물로
HRID 970265 반응식
HRID 970265반응물로
HRID 1295536 반응식
HRID 1295536반응물로
HRID 1296337 반응식
HRID 1296337반응물로
HRID 1363907 반응식
HRID 1363907반응물로
HRID 1788651 반응식
HRID 1788651반응물로
HRID 2085903 반응식
HRID 2085903반응물로

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
DTXSID8044331
ChEMBL
CHEMBL501867
EC Number
218-190-0
BRN
3924631 · 3924631
안정성
2 · 제공된 대로 구매일로부터 2년 동안 안정적입니다. 증류수 용액은 -20°에서 최대 3개월 동안 보관할 수 있습니다.
주요 응용
의약품(소분자)
InChIKey
AQTQHPDCURKLKT-HSMPTBRCNA-N
SMILES
OS(O)(=O)=O.CC[C@]1(O)CC2CN(CCc3c([nH]c4ccccc34)[C@@](C2)(C(=O)OC)c5cc6c(cc5OC)N(C=O)C7[C@](O)([C@H](OC(C)=O)[C@]8(CC)C=CCN9CC[C@]67C89)C(=O)OC)C1
EPA
Vincristine sulfate (2068-78-2)

화학적 성질

Crystalline Solid

Reactive GroupAlcohols and Polyols
Reactivity ProfileSensitive to hydrolysis, oxidation and heat. Incompatible with strong oxidizing agents. (NTP, 1992).
Air and Water ReactionsVery hygroscopic. Water soluble.
Hazard Classes and CategoriesAcute Tox. 2 (91.5%)

안전 및 보호

Fire FightingFires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher. A water spray may also be used. (NTP, 1992)
First Aid · 1건

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.

Nonfire Spill Response · 1건

SMALL SPILLS AND LEAKAGE: If you spill this chemical, you should dampen the solid spill material with water, then transfer the dampened material to a suitable container. Use absorbent paper dampened with water to pick up any remaining material. Seal your contaminated clothing and the absorbent paper in a vapor-tight plastic bag for eventual disposal. Wash all contaminated surfaces with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.

Isolation and EvacuationExcerpt from ERG Guide 151 [Substances - Toxic (Non-Combustible)]:
Personal Protective Equipment (PPE) · 1건

RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter. (NTP, 1992)

독성 정보

Toxicity Summary · 1건

The antitumor activity of Vincristine is thought to be due primarily to inhibition of mitosis at metaphase through its interaction with tubulin. Like other vinca alkaloids, Vincristine may also interfere with: 1) amino acid, cyclic AMP, and glutathione metabolism, 2) calmodulin-dependent Ca<sup>2+</sup>-transport ATPase activity, 3) cellular respiration, and 4) nucleic acid and lipid biosynthesis.

Carcinogen Classification · 6건

Vincristine sulfate

Group 3: Not classifiable as to its carcinogenicity to humans

Volume 26: (1981) Some Antineoplastic and Immunosuppressive Agents

1987

1987

Vincristine sulfate is not classifiable as to its carcinogenicity to humans (Group 3). Vincristine is part of MOPP, a combination chemotherapy regimen that is carcinogenic to humans (Group 1). (L135)

Drug Induced Liver Injury · 6건

Drug Induced Liver Injury Rank (DILIrank 2.0)

Vincristine sulfate

vLess-DILI-concern

8

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
Toxicity DataIVN-RAT LD<sub>50</sub> 1300 mg/kg; IPR-MUS LD<sub>50</sub> 5.2 mg/kg.

안전 데이터

wgk
3
rtecs
OH6340000
ridadr
UN 2811 6.1/PG 2
독성
LD50 intraperitoneal in mouse: 3mg/kg
HS 번호
29399990
risk_code
61-36/37/38-63-23/24/25-68-62-25
hazard_code
T
safety_code
22-24/25-53-45-37/39-26-36/37/39-36/37
포장분류
II
위험 등급
6.1(a)
F 고인화성물질
8-10
Hazard Classifications
Acute Tox. 2 OralMuta. 2Repr. 2
스토리지 클래스
6.1A - Combustible acute toxic Cat. 1 and 2very toxic hazardous materials

상류 원료

황산벤젠

하류 제품

Desacetylvinblastineamide